Literature DB >> 2839989

Nicotinamide as a rapid-acting inhibitor of renal brush-border phosphate transport.

K I Wu1, R A Bacon, H A Al-Mahrouq, S A Kempson.   

Abstract

Administration of nicotinamide to rats produces specific dose-dependent inhibition of Na+-dependent phosphate transport across the renal brush-border membrane (BBM) and an increase in urinary excretion of phosphate. The intracellular mechanism of action of nicotinamide is not well established. As a step in this direction, the present studies determined whether nicotinamide was a rapid- or slow-acting regulator of the BBM phosphate transport system. Nicotinamide (0.5 g/kg) inhibited Na+-dependent BBM phosphate transport under conditions when de novo protein synthesis was inhibited by cycloheximide (1.0 mg/kg). Furthermore, the degree of inhibition was not different from that achieved by nicotinamide alone, suggesting that the action of nicotinamide does not require de novo protein synthesis. Studies on the time course of the onset of nicotinamide action revealed inhibition of BBM phosphate transport within 1 h after injection of nicotinamide, even in rats pretreated with cycloheximide. The rapid response to nicotinamide and its independence of de novo protein synthesis characterize nicotinamide as a rapid-acting regulator of the Na+-dependent phosphate transport system in renal BBM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839989     DOI: 10.1152/ajprenal.1988.255.1.F15

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.

Authors:  Rakesh Malhotra; Ronit Katz; Andrew Hoofnagle; Andrew Bostom; Dena E Rifkin; Ruth Mcbride; Jeffrey Probstfield; Geoffrey Block; Joachim H Ix
Journal:  Clin J Am Soc Nephrol       Date:  2017-12-05       Impact factor: 8.237

2.  Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium.

Authors:  Austin M Reilly; Amie K Gray; Sharon M Moe; Shoji Ichikawa
Journal:  Bone       Date:  2014-07-04       Impact factor: 4.398

3.  Hepatectomy-related hypophosphatemia: a novel phosphaturic factor in the liver-kidney axis.

Authors:  Kengo Nomura; Sawako Tatsumi; Atsumi Miyagawa; Yuji Shiozaki; Shohei Sasaki; Ichiro Kaneko; Mikiko Ito; Shinsuke Kido; Hiroko Segawa; Mitsue Sano; Tsutomu Fukuwatari; Katsumi Shibata; Ken-ichi Miyamoto
Journal:  J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 10.121

Review 4.  Nicotinamide and phosphate homeostasis in chronic kidney disease.

Authors:  Charles Ginsberg; Joachim H Ix
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

Review 5.  Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.

Authors:  Denis Fouque; Marc Vervloet; Markus Ketteler
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

6.  Niacin in patients with chronic kidney disease: Is it effective and safe?

Authors:  Cheol Whee Park
Journal:  Kidney Res Clin Pract       Date:  2013-02-08

Review 7.  The role of SLC34A2 in intestinal phosphate absorption and phosphate homeostasis.

Authors:  Joanne Marks
Journal:  Pflugers Arch       Date:  2018-10-20       Impact factor: 3.657

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.